BioNTech eases 2024 revenue outlook despite hefty Covid vaccine third-quarter sales

Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine uptake, pricing and seasonal variations. The company’s €1.2 billion ($1.3 billion) in Q3 revenues significantly beat analyst ...